Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, shares her experiences from the American Society of Clinical Oncology's June 2017 Conference. She also updates us on the latest research from the conference as it relates to metastatic breast cancer.
36. Weill Cornell Breast Center Clinical Trials – Adjuvant Trials
ER+/PR+ TNBC HER2+ BRCA+
• S1207 : Phase III
Randomized, Placebo-
Controlled Clinical
Trial EvaluaFng The
Use of Adjuvant
Endocrine Therapy +/-
One Year of
Everolimus
• POSITIVE: Pregnancy
Outcome and Safety
of InterrupFng
Therapy for Women
with Endocrine
Responsive Breast
Cancer
• S1418 : A
Randomized, Phase III
Trial to Evaluate the
Efficacy and Safety of
MK-3475 as Adjuvant
Therapy for Triple
Receptor-NegaFve
Breast Cancer
• EA1131: PlaFnum
Based Chemotherapy
or ObservaFon in
TreaFng PaFents With
Residual Triple-
NegaFve Basal-Like
Breast Cancer
Following
Neoadjuvant
Chemotherapy
• NSABP B55 : A
randomized phase III
Study to access the
efficacy and safety of
olaparib versus
placebo as adjuvant
treatment in pt with
Germline BRCA1/2
mutaFons
Targeted
SupporFve
Care/
CorrelaFve/
Biobank
• Triple Nega<ve Breast
Cancer Program:
Clinical Database and
Tissue CollecFon
Project for the Study of
Breast Cancer
• Stress-Reduc<on &
Self-Healing: A Pilot
Study of Guided
MeditaFon
• Precision Medicine: To
idenFfy the frequency
and rate of acFonable
mutaFons in advanced
cancers
• Biomarkers: To idenFfy
the frequency and rate
of acFonable
mutaFons in advanced
cancers
• SCP Sa<sfac<on
Survey: PaFent and
Physician SaFsfacFon
Survey of Survivorship
Care Plans
37. Weill Cornell Breast Center Clinical Trials – MetastaFc Trials
ER+/PR+ TNBC HER2+ BRCA+
• E2112: A Randomized
Phase III Trial of
Endocrine Therapy
plus EnFnostat/
Placebo in Men and
Women with Hormone
Receptor-PosiFve
Advanced Breast
Cancer
• IMMU-132-01: A
Phase II Study of
IMMU-132 (hRS7-
SN38 AnFbody Drug
Conjugate) in PaFents
with Epithelial Cancer
• MILLENNIUM: A Phase
1b/2 Study of
MLN0128 in
CombinaFon With
Exemestane or
Fulvestrant Therapy in
Postmenopausal
Women With ER+/
HER2- Advanced or
MetastaFc Breast
Cancer
• AAAM1906: Phase II
Trial of RuxoliFnib in
CombinaFon with
Trastuzumab in
MetastaFc HER2
PosiFve Breast Cancer
• PUMA: A Phase III Trial
of NeraFnib +
Capecitabine Versus
LapaFnib + Capecitbine
In PaFents With HER2+
MetastaFc Breast
Cancer
• Macrogenics: A Phase
3, Randomized Study
of Margetuximab Plus
Chemotherapy vs
Trastuzumab Plus
Chemotherapy in the
Treatment of PaFents
with HER2+ MetastaFc
Breast Cancer
• CELLDEX : A
Randomized
MulFcenter Pivotal
Study of CDX-011
(CR011-vcMMAE) in
PaFents with
MetastaFc, GPNMB
Over-Expressing,
Triple-NegaFve Breast
Cancer
• Rexahn: A MulF-
Center, Dose Finding,
Open Label, Phase 1
study of RX_5902 in
Subjects with
Advanced or
MetastaFc Solid
Tumors
• Oncotherapy: A Phase
I Study of OTS167PO, a
MELK inhibitor, in
PaFents with
Advanced, Triple
NegaFve Breast
Cancer
• Pharma Mar: A
MulFcenter Phase II
Clinical Trial of
PM01183 in BRCA 1/2-
Associated or
Unselected MetastaFc
Breast Cancer
Targeted
• Genentech Pathway: Open-
label Phase IIa Study
EvaluaFng Trastuzumab/
pertuzumab, ErloFnib,
Vemurafenib, and
Vismodegib in Pt's W/
Advanced Solid Tumors
With MutaFons or Gene
Expression AbnormaliFes
PredicFve of Response to
One of These Agents
• LY2157299: LY2157299
Monohydrate and
Radiotherapy in MetastaFc
Breast Cancer
• TLR7: Phase I/II study of
TLR7 agonist Imiquimod,
Cyclophosphamide, and
Radiotherapy in Breast
Cancer PaFents with Chest
Wall Recurrence or Skin
Metastases
SupporFve
Care/
CorrelaFve/
Biobank
• Triple Nega<ve Breast
Cancer Program:
Clinical Database and
Tissue CollecFon
Project for the Study of
Breast Cancer
• Stress-Reduc<on &
Self-Healing: A Pilot
Study of Guided
MeditaFon
• Precision Medicine: To
idenFfy the frequency
and rate of acFonable
mutaFons in advanced
cancers
• Biomarkers: To idenFfy
the frequency and rate
of acFonable
mutaFons in advanced
cancers
• SCP Sa<sfac<on
Survey: PaFent and
Physician SaFsfacFon
Survey of Survivorship
Care Plans